THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Susanna Ulahannan to Humans

This is a "connection" page, showing publications Susanna Ulahannan has written about Humans.
Connection Strength

0.129
  1. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology. 2014 Nov; 60(5):1637-44.
    View in: PubMed
    Score: 0.027
  2. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest. 2011 May; 29(4):325-37.
    View in: PubMed
    Score: 0.021
  3. A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2022 Mar 01; 28(5):882-892.
    View in: PubMed
    Score: 0.011
  4. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021 09; 16(5):569-589.
    View in: PubMed
    Score: 0.011
  5. Reversible HER2 antibody-drug conjugate-induced ocular toxicity. Can J Ophthalmol. 2022 04; 57(2):118-126.
    View in: PubMed
    Score: 0.010
  6. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874.
    View in: PubMed
    Score: 0.010
  7. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clin Cancer Res. 2017 Aug 15; 23(16):4633-4641.
    View in: PubMed
    Score: 0.008
  8. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017 03; 66(3):545-551.
    View in: PubMed
    Score: 0.008
  9. Pancreatic Squamous Cell Carcinoma: A Population-Based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes. Pancreas. 2016 11; 45(10):1432-1437.
    View in: PubMed
    Score: 0.008
  10. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. Int J Cancer. 2016 10 01; 139(7):1648-57.
    View in: PubMed
    Score: 0.008
  11. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016 06 01; 122(11):1757-65.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES